2012年1月4日，據(jù)《每日科學(xué)》報(bào)道,，根據(jù)發(fā)表于《癌癥預(yù)防研究》期刊（一種美國癌癥研究協(xié)會期刊）上的一項(xiàng)研究結(jié)果,， 接受抗雌激素補(bǔ)充劑的乳腺癌女性患者可能會減少患黑色素瘤的風(fēng)險。
Christine Bouchardy,，醫(yī)學(xué)博士,，日內(nèi)瓦大學(xué)教授和日內(nèi)瓦癌癥登記處的負(fù)責(zé)人，和他的同事分析了7360名在1980年和2005年之間患乳腺癌婦女的數(shù)據(jù),。這些婦女中大約有一半人（54％）接受了抗雌激素治療。
研究人員追蹤這些患者一直到2008年,，并在后續(xù)期間記錄了34例黑色素瘤病例,。與接受抗雌激素治療的患者相比，未接受抗雌激素治療的患者患黑色素瘤的風(fēng)險高出60％,。
據(jù)Bouchardy,，對雌激素在乳腺癌中作用持續(xù)增加的關(guān)注使科學(xué)家們開始思考，在其他癌癥中雌激素發(fā)揮著什么作用,。 "這些數(shù)據(jù)強(qiáng)化了先前的假設(shè),，即雌激素在黑色素瘤的發(fā)生中發(fā)揮了作用，"她說,。
Bouchardy說,，這可能是由于雌激素與黑色素細(xì)胞水平及人體皮膚中黑色素產(chǎn)生的增加有關(guān)，這些與早期黑色素瘤相關(guān),。然而,，她警告廣泛的抗雌激素補(bǔ)充防止總?cè)丝谥械暮谏亓觥?/p>
"這些結(jié)果需要在其他研究中進(jìn)一步重復(fù)，特別是要考慮到這種藥物眾多的副作用,，"Bouchardy說,。
這項(xiàng)研究由一個非營利性組織--瑞士癌癥研究基金會資助。（生物谷bioon.com）
doi:10.1158/1940-6207.CAPR-11-0332
PMC:
PMID:
.Antiestrogen Therapy for Breast Cancer Modifies the Risk of Subsequent Cutaneous Melanoma.
C. Huber, C. Bouchardy, R. Schaffar, I. Neyroud-Caspar, G. Vlastos, F.-A. Le Gal, E. Rapiti, S. Benhamou.
Abstract： Increased risk of secondary melanoma after breast cancer has been reported. Several lines of evidence suggest that elevated estrogen levels may be implicated in melanoma etiology. Accordingly, use of antiestrogens should be associated with decreased risk of melanoma. We compared melanoma incidence among a cohort of breast cancer patients with and without antiestrogen therapy, with data from the Geneva Cancer Registry. The cohort consisted of 7,360 women diagnosed with breast cancer between 1980 and 2005. About 54% of these patients received antiestrogens. All women were followed until December 2008. We compared cutaneous melanoma incidence rates among patients with and without antiestrogens with those expected in the general population by age and period standardized incidence ratios (SIR). A total of 34 women developed a melanoma during the follow-up period. Compared with the general population, the risk of melanoma was higher for patients who did not receive antiestrogens (SIR: 1.60, 95% CI: 1.08–2.12,P = 0.02). On the contrary, the risk was close to 1 (SIR: 0.98, 95% CI: 0.40–1.56, P = 0.57) for patients who received antiestrogen therapy. This study suggests that antiestrogen therapy modifies the risk of melanoma after breast cancer. Although our results are in agreement with the hypothesis that estrogens could play a role in melanoma occurrence, they need to be replicated in a larger study with data on potential confounders. Cancer Prev Res; 5(1); 82–88. ©2011 AACR.
